Anti-VEGF Therapies and Ocular Systemic Impact Update -

Overview
Supported by an unrestricted educational grant from Regeneron Pharmaceuticals
Learning Objectives
Upon completion of this activity participants should be able to: • Understand the most recent monotherapy and combination therapy clinical study evidence using available antiVEGF therapies for common retinal diseases, including AMD, RVO and DME • Discuss the ocular and systemic effects of anti-VEGF therapies and how to educate patients on appropriate expectations • Develop plans to initiate treatment for conditions such as AMD, RVO and DME using anti-VEGF agents, as well as better understand when to change therapeutic strategies
Accreditation
Accreditation Statement This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Evolve Medical Education and Retina Today. Credit Designation Statement Evolve Medical Education LLC is accredited by the ACCME to provide continuing education for physicians. Evolve Medical Education LLC designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit. ™ Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Participation Method
Participants should read the CME activity in its entirety. After reviewing the material, please complete the self-assessment test, which consists of a series of multiple choice questions. To answer these questions online and receive real-time results, please visit www.dulaneyfoundation.org and click “Online Courses.” Upon completing the activity and achieving a passing score of over 70% on the self-assessment test, you may print out a CME credit letter awarding 1 AMA PRA Category 1 Credit.™ The estimated time to complete this activity is 1 hour.
Faculty and Disclosures
DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflicts of interest relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all conflicts of interest prior to this educational activity.
David S. Boyer, MD had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board/Speaker’s Bureau: Aerpio Therapeutics; Alcon, Inc; Allegro Ophthalmics, LLC; Allergan, Inc.; Bausch + Lomb Incorporated; Bayer; Genentech, Inc.; KalVista Pharmaceuticals; Neurotech Pharmaceuticals; Novartis; Ora, Inc.; Pfizer Inc.; QLT Inc.; Regeneron Pharmaceuticals, Inc.; Roche USA; and ThromboGenics. Stockholder: Allegro Ophthalmics, LLC; Other: Data Safety Monitoring Board: StemCells, Inc.
Peter K. Kaiser, MD had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board: Alcon, Inc; Alimera Sciences; Allegro Ophthalmics, LLC; Bayer; Biogen Idec; Chengdu Kanghong Biotechnology Co, Ltd; DigiSight Technologies Inc; Genentech, Inc; InSitu; Novartis; OHR Pharmaceutical Inc; Ophthotech Corporation; Oraya Therapeutics, Inc; Regeneron Pharmaceuticals, Inc; and ThromboGenics NV; Stockholder: Allegro Ophthalmics, LLC; OHR Pharmaceutical Inc; and Ophthotech Corporation.
John W. Kitchens, MD had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board: Allergan, Inc; Genentech, Inc.; Regeneron Pharmaceuticals, Inc.; Synergetics USA, Inc.; and ThromboGenics.
Editorial Support Disclosure Cheryl Cavanaugh, MS; Michelle Dalton and Melanie Lawler, PhD have no relevant commercial interests to disclose.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of The Dulaney Foundation and Retina Today.
System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
  Apple Safari for Mac OS and iOS
  Mozilla Firefox for Windows, Mac OS, iOS, and Android
  Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Publication Dates
Expiration Date: 10/31/2016

Recommended

Title